ID   NOR-P1
AC   CVCL_4716
SY   Nor-P1
DR   BTO; BTO_0003533
DR   CLO; CLO_0050103
DR   BioSample; SAMN03472013
DR   FANTOM5_SSTAR; 10698-109G5
DR   RCB; RCB2139
DR   TKG; TKG 0630
DR   Wikidata; Q54930908
RX   PubMed=10822130;
CC   Population: Japanese.
CC   Doubling time: 16 hours (PubMed=10822130).
CC   Discontinued: RCB; RCB2139; true.
CC   Discontinued: TKG; TKG 0630; true.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): RCB=RCB2139; TKG=TKG 0630
ST   Amelogenin: X,Y
ST   CSF1PO: 7,10
ST   D13S317: 11
ST   D16S539: 9,10 (TKG=TKG 0630)
ST   D16S539: 10 (RCB=RCB2139)
ST   D5S818: 10,11
ST   D7S820: 10,11
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   79Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 18
//
RX   PubMed=10822130; DOI=10.1016/S0304-3835(00)00421-3;
RA   Sato, Norihiro
RA   Mizumoto, Kazuhiro
RA   Beppu, Kiichiro
RA   Maehara, Naoki
RA   Kusumoto, Masahiro
RA   Nabae, Toshinaga
RA   Morisaki, Takashi
RA   Katano, Mitsuo
RA   Tanaka, Masao
RT   "Establishment of a new human pancreatic cancer cell line, NOR-P1,
RT   with high angiogenic activity and metastatic potential.";
RL   Cancer Lett. 155:153-161(2000).
//